Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre Otwock, Borowa 14/18, 05-400, Otwock, Poland.
1st Department of Cardiology, University of Medical Sciences, Poznan, Poland.
BMC Pulm Med. 2017 Dec 2;17(1):162. doi: 10.1186/s12890-017-0474-7.
Subcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary arterial hypertension (PAH). Due to local pain it can cause a deterioration of heart related quality of life (HRQoL) or even abandonment of treatment. The aim of this paper was to assess the feasibility of treatment with intravenous treprostinil administered by means of the Lenus Pro® implantable pump.
This was a retrospective, multi-center study involving 12 patients (8 females) with PAH treated with a subcutaneous infusion of treprostinil with intolerable pain at the infusion site. Clinical evaluation, including HRQoL assessment with SF-36 questionnaire was performed, before pump implantation and 2-9 months after. The median time of follow-up time was 14 months (4-29 months).
After implantation of the Lenus Pro® pump, no statistically significant changes were observed in the 6-min walking distance and NT-proBNP. After implantation 50% of patients were in II WHO functional class (33% before, p = 0,59). There was a significant improvement in HRQoL within the Physical Component Score (28 ± 7 vs 38 ± 8 pts., p < 0,001) and in specific domains of SF-36 form: physical role (31 ± 7 pts. vs. 41 ± 12 pts., p = 0,03), bodily pain (31 ± 12 vs. 50 ± 14 pts., p = 0,02), and vitality (37 ± 8 pts. vs. 50 ± 14 pts., p = 0,03). During the periprocedural period, one patient developed a recurrent haematoma at the implantation site. During follow-up in one patient, the drug delivering cannula slipped out of the subclavian vein, what required repositioning repeated twice, and in another patient an unexpected increase in the drug administration rate was observed.
In patients with PAH who do not tolerate subcutaneous infusion of treprostinil, the use of the Lenus Pro® implantable pump results in significant subjective improvement of vitality and physical aspect of the HRQoL with acceptable safety profile.
皮下注射曲前列尼尔是一种前列环素类似物,用于治疗肺动脉高压(PAH)。由于其会引起局部疼痛,可能会导致与心脏相关的生活质量(HRQoL)恶化,甚至导致治疗中断。本文旨在评估使用 Lenus Pro®植入式输液泵进行静脉注射曲前列尼尔治疗的可行性。
这是一项回顾性、多中心研究,共纳入 12 名(8 名女性)因输注部位疼痛不耐受而接受曲前列尼尔皮下输注治疗的 PAH 患者。在泵植入前和植入后 2-9 个月进行临床评估,包括使用 SF-36 问卷进行 HRQoL 评估。中位随访时间为 14 个月(4-29 个月)。
植入 Lenus Pro®输液泵后,6 分钟步行距离和 NT-proBNP 无统计学显著变化。植入后 50%的患者处于 II 级 WHO 功能状态(植入前为 33%,p=0.59)。在生理成分评分(28±7 分 vs 38±8 分,p<0.001)和 SF-36 特定领域内,HRQoL 有显著改善:身体角色(31±7 分 vs 41±12 分,p=0.03)、躯体疼痛(31±12 分 vs 50±14 分,p=0.02)和活力(37±8 分 vs 50±14 分,p=0.03)。围手术期,1 例患者发生植入部位复发性血肿。在 1 例患者的随访中,药物输送套管从锁骨下静脉滑出,需要重复两次重新定位,另 1 例患者观察到药物给药率意外增加。
对于不能耐受皮下输注曲前列尼尔的 PAH 患者,使用 Lenus Pro®植入式输液泵可显著改善活力和 HRQoL 的生理方面,且安全性可接受。